Rhythm Pharmaceuticals Inc
(MEX:RYTM)
MXN
680.21
0 (0%)
Market Cap: 60.59 Bil
Enterprise Value: 57.08 Bil
PE Ratio: 0
PB Ratio: 76.57
GF Score: 57/100 Rhythm Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 03:05PM GMT
David Neil Lebowitz
Morgan Stanley, Research Division - VP
I'm one of the biotechnology analysts at Morgan Stanley, David Lebowitz. And I have with me on the stage from Rhythm Pharmaceuticals, CEO, Keith Gottesdiener. I'm sorry.
Keith Michael Gottesdiener
Rhythm Pharmaceuticals, Inc. - President, CEO & Director
No problem, no one ever uses my last name for exactly that reason.
David Neil Lebowitz
Morgan Stanley, Research Division - VP
I'll call you Keith G. Rhythm is a company that develops therapies for ultra-rare forms of genetic obesity. If you could, I guess, give us a top level just on the company and bring us up to speed on the recent updates.
Keith Michael Gottesdiener
Rhythm Pharmaceuticals, Inc. - President, CEO & Director
Sure. So Rhythm is a company, as David said, that focuses on rare genetic causes of obesity, and we are focused on the pathway in the brain called the melanocortin-4, MC4 pathway, which is probably the key pathway in the brain that
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot